Yong Cui1, Sandra L Deming-Halverson1, Martha J Shrubsole1, Alicia Beeghly-Fadiel1, Alecia M Fair2, Maureen Sanderson3, Xiao-Ou Shu1, Mark C Kelley4, Wei Zheng5. 1. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN. 2. Vanderbilt Institute of Clinical Translational Research, Vanderbilt University School of Medicine, Nashville, TN. 3. Meharry/Vanderbilt Cancer Partnership, Nashville General Hospital, Nashville, TN. 4. Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN. 5. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN. Electronic address: wei.zheng@vanderbilt.edu.
Abstract
BACKGROUND: Causes of racial disparities in breast cancer incidence and mortality between white and African American women remain unclear. This study evaluated associations of menstrual and reproductive factors with breast cancer risk by race and cancer subtypes. PATIENTS AND METHODS: Included in the study were 1866 breast cancer cases and 2306 controls recruited in the Nashville Breast Health Study, a population-based case-control study. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: African American women were more likely to have estrogen receptor-negative (ER(-)), progesterone receptor-negative (PR(-)), and triple-negative (ER(-)PR(-)HER2(-)) breast cancer than white women. Age at menarche (≥ 14 years) and multiparity (≥ 3 live births) were inversely associated with ER(+) tumors only, whereas late age at first live birth (> 30 years) and nulliparity were associated with elevated risk; such associations were predominantly seen in white women (OR = 0.70, 95% CI = 0.55-0.88; OR = 0.72, 95% CI = 0.56-0.92; OR = 1.42, 95% CI = 1.13-1.79; OR = 1.32, 95% CI = 1.06-1.63, respectively). Age at menopause between 47 and 51 years was associated with elevated risk of ER(-) tumors in both white and African American women. Among women who had natural menopause, positive association between ever-use of hormone replacement therapy and breast cancer risk was seen in white women only (OR = 1.39, 95% CI = 1.03-1.87). CONCLUSION: This study suggests that certain hormone-related factors are differentially associated with risk of breast cancer subtypes, and these associations also differ by race.
BACKGROUND: Causes of racial disparities in breast cancer incidence and mortality between white and African American women remain unclear. This study evaluated associations of menstrual and reproductive factors with breast cancer risk by race and cancer subtypes. PATIENTS AND METHODS: Included in the study were 1866 breast cancer cases and 2306 controls recruited in the Nashville Breast Health Study, a population-based case-control study. Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: African American women were more likely to have estrogen receptor-negative (ER(-)), progesterone receptor-negative (PR(-)), and triple-negative (ER(-)PR(-)HER2(-)) breast cancer than white women. Age at menarche (≥ 14 years) and multiparity (≥ 3 live births) were inversely associated with ER(+) tumors only, whereas late age at first live birth (> 30 years) and nulliparity were associated with elevated risk; such associations were predominantly seen in white women (OR = 0.70, 95% CI = 0.55-0.88; OR = 0.72, 95% CI = 0.56-0.92; OR = 1.42, 95% CI = 1.13-1.79; OR = 1.32, 95% CI = 1.06-1.63, respectively). Age at menopause between 47 and 51 years was associated with elevated risk of ER(-) tumors in both white and African American women. Among women who had natural menopause, positive association between ever-use of hormone replacement therapy and breast cancer risk was seen in white women only (OR = 1.39, 95% CI = 1.03-1.87). CONCLUSION: This study suggests that certain hormone-related factors are differentially associated with risk of breast cancer subtypes, and these associations also differ by race.
Authors: Xiaohong R Yang; Mark E Sherman; David L Rimm; Jolanta Lissowska; Louise A Brinton; Beata Peplonska; Stephen M Hewitt; William F Anderson; Neonila Szeszenia-Dabrowska; Alicja Bardin-Mikolajczak; Witold Zatonski; Richard Cartun; Daniza Mandich; Grzegorz Rymkiewicz; Marcin Ligaj; Stanislaw Lukaszek; Radzisaw Kordek; Montserrat García-Closas Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-03 Impact factor: 4.254
Authors: Michelle D Althuis; Jennifer H Fergenbaum; Montserrat Garcia-Closas; Louise A Brinton; M Patricia Madigan; Mark E Sherman Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-10 Impact factor: 4.254
Authors: Beth A Jones; Stanislav V Kasl; Christine L Howe; Mary Lachman; Robert Dubrow; Mary McCrea Curnen; Hosanna Soler-Vila; Alicia Beeghly; Fenghai Duan; Patricia Owens Journal: Cancer Date: 2004-09-15 Impact factor: 6.860
Authors: Nathan L DeBono; Whitney R Robinson; Jennifer L Lund; Chiu Kit Tse; Patricia G Moorman; Andrew F Olshan; Melissa A Troester Journal: J Womens Health (Larchmt) Date: 2017-06-01 Impact factor: 2.681
Authors: Christine B Ambrosone; Gary Zirpoli; Chi-Chen Hong; Song Yao; Melissa A Troester; Elisa V Bandera; Pepper Schedin; Traci N Bethea; Virginia Borges; Song-Yi Park; Dhyan Chandra; Lynn Rosenberg; Laurence N Kolonel; Andrew F Olshan; Julie R Palmer Journal: J Natl Cancer Inst Date: 2015-06-17 Impact factor: 13.506
Authors: Danja Sarink; Kami K White; Lenora W M Loo; Anna H Wu; Lynne R Wilkens; Loïc Le Marchand; Song-Yi Park; V Wendy Setiawan; Melissa A Merritt Journal: Int J Cancer Date: 2021-09-16 Impact factor: 7.396
Authors: Kimberly A Bertrand; Traci N Bethea; Lucile L Adams-Campbell; Lynn Rosenberg; Julie R Palmer Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-18 Impact factor: 4.254
Authors: Lynn Rosenberg; Traci N Bethea; Emma Viscidi; Chi-Chen Hong; Melissa A Troester; Elisa V Bandera; Christopher A Haiman; Laurence N Kolonel; Andrew F Olshan; Christine B Ambrosone; Julie R Palmer Journal: J Natl Cancer Inst Date: 2015-11-26 Impact factor: 13.506
Authors: Kara Keun Lee; Lavanya Rishishwar; Dongjo Ban; Shashwat Deepali Nagar; Leonardo Mariño-Ramírez; John F McDonald; I King Jordan Journal: Cancer Res Date: 2022-04-01 Impact factor: 13.312
Authors: Esther M John; Amanda I Phipps; Lisa M Hines; Jocelyn Koo; Sue A Ingles; Kathy B Baumgartner; Martha L Slattery; Anna H Wu Journal: Int J Cancer Date: 2020-02-29 Impact factor: 7.396